CLINICAL_TRIALS
trial_result
· 2022-04-14
Clinical Trial Update: Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056 [Phase 2]
Summary
Phase 2 open-label study of CDP6038 (Olokizumab) in rheumatoid arthritis completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UCB BIOSCIENCES, Inc. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2022-04-14